Lawlis V Bryan

SEC CIK: 0001247681

SEC filings (opens in a new tab)

No open-market purchases or sales filed in the past year.

Current role at each company

GERN Geron CorpDirectoras of May 22, 2025
BMRN Biomarin Pharmaceutical IncDirectoras of May 24, 2023
SYRE Spyre Therapeutics, Inc.Directoras of Jun 9, 2022

Open-market trades in the past year

Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.

Bought: –; 0 filings
Sold: –; 0 filings
Net: –; Bought minus sold
Companies: 0; With open-market trades

Trades

Every Form 4 that lists Lawlis V Bryan as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.

Transaction type

Role

Minimum value (USD)

Filed from

Filed to

Filing delay at least (days)

Filing delay at most (days)

GERN Geron Corp

Director3 trades

Insider trades
Filed (ET)	Trade date	Filing delay	Insider	Transaction	Shares	Avg price	Value	Holding change	Flags
May 13, 2025 (view filing)	May 9	4 days	Lawlis V BryanDirector	PPurchase	+13.3K	$1.18	+$15.7K	New position13.3K after
May 17, 2024 (view filing)	May 15	2 days	Lawlis V BryanDirector	SSale	−35.0K	$3.75	−$131.3K	−100.0%0 after	10b5-1
May 11, 2023 (view filing)	May 11	Same day	Lawlis V BryanDirector	SSale	−35.0K	$3.00	−$105.0K	−100.0%0 after	10b5-1

BMRN Biomarin Pharmaceutical Inc